Palisade Bio, Inc.

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing oral phosphodiesterase-4 (PDE4) inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon. Its lead product candidate is PALI-2108, which is currently in a Phase 1b clinical trial for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Fibrostenotic Crohn's disease. The company's technology aims to deliver the drug directly to the site of inflammation in the gastrointestinal tract, potentially improving efficacy and reducing systemic side effects.

Palisade Bio, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol PALI. The company trades in U.S. dollars (USD), as it is based in the United States. Being listed on Nasdaq provides the company with access to a broad base of institutional and retail investors in the U.S. equity markets.

Palisade Bio operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing novel therapies for inflammatory bowel diseases. Biotechnology companies like Palisade Bio typically engage in research and development of drugs based on biological processes, often requiring significant investment and regulatory approvals before products can be commercialized.

Palisade Bio, Inc. is headquartered in Denver, Colorado, United States. The company was founded in 2001, giving it over two decades of history in the biopharmaceutical space. Its operations are primarily focused on the U.S. market, though it has research collaborations and license agreements with entities such as Giiant Pharma, Inc. and the Regents of the University of California, as well as a co-development and distribution agreement with Newsoara Biopharma Co., Ltd.

Palisade Bio has established several strategic partnerships to advance its drug development programs. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds. Additionally, the company holds a license agreement with the Regents of the University of California solely for maintaining the Newsoara Co-Development. It also has a co-development and distribution agreement with Newsoara Biopharma Co., Ltd., which likely supports the development and potential commercialization of its product candidates in certain markets.